Precision BioSciences has signed a genome editing deal worth up to $1.6 billion with Baxalta, with aims to develop an allogenic CAR-T therapeutic. North Carolina-based Precision BioSciences will receive $105 million up front in the deal.
The two companies will develop CAR-T therapies for up to six unique targets, with the first slated to enter human trials next year.
CAR-T therapy isolates immune cells from cancer patients’ blood, and reengineers them to attack tumor cells. Precision BioSciences, a decade-old Duke spinout, has developed what it calls ARCUS genome editing technology that allows the production of CAR-T cells derived from healthy donors – as opposed to extracting them from patients.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The idea here is to help scale the manufacturing capabilities of CAR-T therapies, which can be difficult when individualizing the therapies to the point of extracting a patient’s own cell.
Baxalta has a number of products in its pipeline in the immunology and oncology spaces, including a broad spectrum of biologics. An allogeneic CAR-T approach – which many have found to be difficult to achieve – could be a powerful addition to its portfolio.
“Combining Precision BioSciences’ ARCUS technology with Baxalta’s global infrastructure, expertise and growing immuno-oncology portfolio is a synergistic approach that we believe has the potential to make disruptive approaches available to people with a range of underserved cancers,” David Meek, president of oncology at Baxalta, said in a statement.
Precision BioSciences has been tasked with all early stage work up through Phase 2, and Baxalta has the exclusive right to conduct late-stage development and commercialization. On top of the $105 million up front, potential royalties and milestones could make this deal worth up to $1.6 billion.
